Molecular Partners Ag (MOLN) Interest & Investment Income (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest & Investment Income of $395.87 for Q1 2026, down 29.1% year-on-year from $558.35 in Q1 2025, and up 100.01% on a QoQ basis from -$4.4 million in Q4 2025.
Molecular Partners Ag (MOLN) Interest & Investment Income (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest & Investment Income for 7 consecutive years, with $395.87 the latest figure, recorded in Q1 2026.
- Quarterly Interest & Investment Income fell 29.1% year-over-year to $395.87 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (down 153.29% YoY) and the FY2025 annual result came in at -$4.4 million, down 153.28% from the prior year.
- Interest & Investment Income climbed to $395.87 in Q1 2026 per MOLN's latest filing, from -$4.4 million in the prior quarter.
- Over the last five years, Interest & Investment Income for MOLN reached as high as $8.2 million in Q4 2024 and fell as low as -$4.4 million in Q4 2025.
- A 5-year average of $817261.8 and a median of $1008.5 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 840.27% — and 2025, when it plunged 153.33%.
- Year by year, Interest & Investment Income stood at $1.9 million in 2022, then jumped by 150.39% to $4.8 million in 2023, then jumped by 70.42% to $8.2 million in 2024, then plunged by 153.33% to -$4.4 million in 2025, then soared by 100.01% to $395.87 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $395.87, -$4.4 million, and $457.54 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Molecular Partners Ag | 149.27 Mn | 149.27 Mn | - | 395.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 395.87 |
| Dec 31, 2025 | -4.38 Mn |
| Sep 30, 2025 | 457.54 |
| Jun 30, 2025 | 507.31 |
| Mar 31, 2025 | 558.35 |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 828.72 |
| Jun 30, 2024 | 1,008.48 |
| Mar 31, 2024 | 5,204.83 |
| Dec 31, 2023 | 4.82 Mn |
| Sep 30, 2023 | 2,333.37 |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 937.37 |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 1,539.72 |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 891.15 |
| Dec 31, 2021 | 204,749.66 |
| Sep 30, 2021 | 717.74 |
| Jun 30, 2021 | 1.69 Mn |